• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解锁呋喃妥因:了解肠杆菌科细菌的分子作用机制及耐药性

Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales.

作者信息

Khamari Balaram, Bulagonda Eswarappa Pradeep

机构信息

Department of Biosciences, Sri Sathya Sai Institute of Higher Learning, Prasanthi Nilayam, Puttaparthi, India.

出版信息

Med Princ Pract. 2025;34(2):121-137. doi: 10.1159/000542330. Epub 2024 Oct 29.

DOI:10.1159/000542330
PMID:39471786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11936445/
Abstract

Antimicrobial resistance (AMR) is a global health crisis that has already claimed millions of lives and is projected to affect millions more unless urgent action is taken. Effective control of AMR requires the correct choice and dosage of antibiotics, as well as robust surveillance and research. Understanding the mechanisms of antibiotic action and the emergence of resistance phenotypes along with their genotypes is essential. This knowledge, combined with insights into resistance prevalence and spread, empowers clinicians to propose alternative therapies. Nitrofurantoin, a 70-year-old antibiotic, remains effective for the treatment of uncomplicated lower UTIs. Preventing emergence and spread of nitrofurantoin-resistant superbugs would preserve the efficacy of this antibiotic which is crucial for ongoing and future AMR efforts. Nitrofurantoin resistance evolves slowly, leading to low prevalence compared to other antibiotics. However, it is often linked with extensive drug resistance, complicating treatment outcomes. Even a minor percentage of nitrofurantoin-resistant bacteria can cause significant clinical challenges due to irreversible evolution. While detailed study of these mechanisms can guide the development of strategies to combat nitrofurantoin resistance, early detection of resistant infections is critical for saving lives. The current review aimed to provide a comprehensive analysis of nitrofurantoin's mechanisms of action, resistance evolution, prevalence, and resistance prediction. Our goal is to offer valuable insights for researchers and clinicians to enhance nitrofurantoin use and address the challenges posed by AMR. Antimicrobial resistance (AMR) is a global health crisis that has already claimed millions of lives and is projected to affect millions more unless urgent action is taken. Effective control of AMR requires the correct choice and dosage of antibiotics, as well as robust surveillance and research. Understanding the mechanisms of antibiotic action and the emergence of resistance phenotypes along with their genotypes is essential. This knowledge, combined with insights into resistance prevalence and spread, empowers clinicians to propose alternative therapies. Nitrofurantoin, a 70-year-old antibiotic, remains effective for the treatment of uncomplicated lower UTIs. Preventing emergence and spread of nitrofurantoin-resistant superbugs would preserve the efficacy of this antibiotic which is crucial for ongoing and future AMR efforts. Nitrofurantoin resistance evolves slowly, leading to low prevalence compared to other antibiotics. However, it is often linked with extensive drug resistance, complicating treatment outcomes. Even a minor percentage of nitrofurantoin-resistant bacteria can cause significant clinical challenges due to irreversible evolution. While detailed study of these mechanisms can guide the development of strategies to combat nitrofurantoin resistance, early detection of resistant infections is critical for saving lives. The current review aimed to provide a comprehensive analysis of nitrofurantoin's mechanisms of action, resistance evolution, prevalence, and resistance prediction. Our goal is to offer valuable insights for researchers and clinicians to enhance nitrofurantoin use and address the challenges posed by AMR.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/67b8afa7fe33/mpp-2025-0034-0002-542330_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/2c9f140a1d87/mpp-2025-0034-0002-542330_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/92955f8a4048/mpp-2025-0034-0002-542330_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/67b8afa7fe33/mpp-2025-0034-0002-542330_F03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/2c9f140a1d87/mpp-2025-0034-0002-542330_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/92955f8a4048/mpp-2025-0034-0002-542330_F02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f11/11936445/67b8afa7fe33/mpp-2025-0034-0002-542330_F03.jpg
摘要

抗菌药物耐药性(AMR)是一场全球健康危机,已经夺走了数百万人的生命,预计除非立即采取行动,否则还将影响数百万人。有效控制AMR需要正确选择抗生素及其剂量,以及强有力的监测和研究。了解抗生素的作用机制以及耐药表型及其基因型的出现至关重要。这些知识,再加上对耐药性流行和传播的深入了解,使临床医生能够提出替代疗法。呋喃妥因是一种使用了70年的抗生素,对治疗非复杂性下尿路感染仍然有效。防止对呋喃妥因耐药的超级细菌的出现和传播将保持这种抗生素的疗效,这对于当前和未来应对AMR的努力至关重要。呋喃妥因耐药性发展缓慢,与其他抗生素相比流行率较低。然而,它常常与广泛耐药性相关联,使治疗结果复杂化。即使是一小部分对呋喃妥因耐药的细菌,由于其不可逆转的进化,也会带来重大的临床挑战。虽然对这些机制的详细研究可以指导对抗呋喃妥因耐药性策略的制定,但耐药感染的早期检测对于挽救生命至关重要。本综述旨在对呋喃妥因的作用机制、耐药性演变、流行率和耐药性预测进行全面分析。我们的目标是为研究人员和临床医生提供有价值的见解,以加强呋喃妥因的使用并应对AMR带来的挑战。抗菌药物耐药性(AMR)是一场全球健康危机,已经夺走了数百万人的生命,预计除非立即采取行动,否则还将影响数百万人。有效控制AMR需要正确选择抗生素及其剂量,以及强有力的监测和研究。了解抗生素的作用机制以及耐药表型及其基因型的出现至关重要。这些知识,再加上对耐药性流行和传播的深入了解,使临床医生能够提出替代疗法。呋喃妥因是一种使用了70年的抗生素,对治疗非复杂性下尿路感染仍然有效。防止对呋喃妥因耐药的超级细菌的出现和传播将保持这种抗生素的疗效,这对于当前和未来应对AMR的努力至关重要。呋喃妥因耐药性发展缓慢,与其他抗生素相比流行率较低。然而,它常常与广泛耐药性相关联,使治疗结果复杂化。即使是一小部分对呋喃妥因耐药的细菌,由于其不可逆转的进化,也会带来重大的临床挑战。虽然对这些机制的详细研究可以指导对抗呋喃妥因耐药性策略的制定,但耐药感染的早期检测对于挽救生命至关重要。本综述旨在对呋喃妥因的作用机制、耐药性演变、流行率和耐药性预测进行全面分析。我们的目标是为研究人员和临床医生提供有价值的见解,以加强呋喃妥因的使用并应对AMR带来的挑战。

相似文献

1
Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales.解锁呋喃妥因:了解肠杆菌科细菌的分子作用机制及耐药性
Med Princ Pract. 2025;34(2):121-137. doi: 10.1159/000542330. Epub 2024 Oct 29.
2
Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible .经验性抗生素治疗对非敏感性门诊尿路感染结局的影响。
Microbiol Spectr. 2022 Feb 23;10(1):e0235921. doi: 10.1128/spectrum.02359-21. Epub 2022 Feb 9.
3
[Nitrofurans: a modern treatment for uncomplicated urinary infections?].[硝基呋喃类药物:治疗单纯性泌尿系统感染的现代疗法?]
Pathol Biol (Paris). 2000 Jun;48(5):470-1.
4
Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline.面对耐药性蔓延的下尿路感染的经验性治疗:硝呋太尔的体外有效性研究。
Int J Antimicrob Agents. 2018 Feb;51(2):213-220. doi: 10.1016/j.ijantimicag.2017.10.010. Epub 2017 Oct 27.
5
Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults.年轻健康成年人门诊泌尿道感染中抗菌药物耐药的风险分析。
J Antimicrob Chemother. 2019 Feb 1;74(2):499-502. doi: 10.1093/jac/dky424.
6
Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.产超广谱β-内酰胺酶肠杆菌科:磷霉素、呋喃妥因和替加环素的体外药敏试验。
Med Princ Pract. 2012;21(6):543-7. doi: 10.1159/000339200. Epub 2012 Jun 21.
7
Resistance to nitrofurantoin is an indicator of extensive drug-resistant (XDR) .对呋喃妥因的耐药性是广泛耐药(XDR)的一个指标。
J Med Microbiol. 2021 Apr;70(4). doi: 10.1099/jmm.0.001347.
8
Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.产超广谱β内酰胺酶(ESBL)肠杆菌科导致的尿路感染患者的口服治疗选择。
J Infect Public Health. 2019 Nov-Dec;12(6):843-846. doi: 10.1016/j.jiph.2019.05.012. Epub 2019 Jun 6.
9
Antibiotic treatment failure of uncomplicated urinary tract infections in primary care.初级保健中非复杂性尿路感染的抗生素治疗失败。
Antimicrob Resist Infect Control. 2023 Aug 1;12(1):73. doi: 10.1186/s13756-023-01282-4.
10
Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.在决策和成本分析中,呋喃妥因作为经验性治疗单纯性尿路感染的推荐药物具有优势。
Mayo Clin Proc. 2011 Jun;86(6):480-8. doi: 10.4065/mcp.2010.0800. Epub 2011 May 16.

本文引用的文献

1
Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.在过去的十年(2010 年至 2020 年),印度 ESKAPE 临床分离株的抗菌药物耐药性急剧增加。
Int J Antimicrob Agents. 2024 May;63(5):107125. doi: 10.1016/j.ijantimicag.2024.107125. Epub 2024 Feb 29.
2
High-level nitrofurantoin resistance in a clinical isolate of a comparative genomics and metabolomics analysis.高水平的硝基呋喃妥因耐药性在临床分离株中的比较基因组学和代谢组学分析。
mSystems. 2024 Jan 23;9(1):e0097223. doi: 10.1128/msystems.00972-23. Epub 2023 Dec 11.
3
Nitrofurantoin resistance as an indicator for multidrug resistance: an assessment of urinary tract specimens in England, 2015-19.
呋喃妥因耐药作为多重耐药的指标:2015 - 2019年英格兰泌尿系统标本评估
JAC Antimicrob Resist. 2023 Nov 17;5(6):dlad122. doi: 10.1093/jacamr/dlad122. eCollection 2023 Dec.
4
Nitrofurantoin: what is the evidence for current UK guidance?呋喃妥因:目前英国指南的证据是什么?
J Antimicrob Chemother. 2023 Nov 6;78(11):2605-2611. doi: 10.1093/jac/dkad287.
5
IS-related large-scale deletion of chromosomal regions harbouring the oxygen-insensitive nitroreductase gene causes nitrofurantoin heteroresistance in .IS 相关的染色体大片段缺失导致氧不敏感的硝基还原酶基因丢失,从而引起 对呋喃妥因的异质性耐药。
Microb Genom. 2023 Sep;9(9). doi: 10.1099/mgen.0.001102.
6
Nitrofuran Derivatives Cross-Resistance Evidence-Uropathogenic Nitrofurantoin and Furazidin In Vitro Susceptibility Testing.硝基呋喃衍生物交叉耐药证据——尿路致病性呋喃妥因和痢特灵的体外药敏试验
J Clin Med. 2023 Aug 8;12(16):5166. doi: 10.3390/jcm12165166.
7
Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review.硝基呋喃妥因:在治疗尿路感染中的特性和潜力:一篇叙述性综述。
Front Cell Infect Microbiol. 2023 Jul 27;13:1148603. doi: 10.3389/fcimb.2023.1148603. eCollection 2023.
8
Pervasive Selection for Clinically Relevant Resistance and Media Adaptive Mutations at Very Low Antibiotic Concentrations.在非常低的抗生素浓度下,针对临床相关耐药性和媒体适应性突变的普遍选择。
Mol Biol Evol. 2023 Jan 4;40(1). doi: 10.1093/molbev/msad010.
9
Exploring the in situ evolution of nitrofurantoin resistance in clinically derived uropathogenic Escherichia coli isolates.探讨临床分离的泌尿道致病性大肠埃希菌中呋喃妥因耐药的原位演变。
J Antimicrob Chemother. 2023 Feb 1;78(2):373-379. doi: 10.1093/jac/dkac398.
10
Bacterial Multidrug Efflux Pumps at the Frontline of Antimicrobial Resistance: An Overview.处于抗菌药物耐药性前沿的细菌多药外排泵:概述
Antibiotics (Basel). 2022 Apr 13;11(4):520. doi: 10.3390/antibiotics11040520.